Madrigal Pharmaceuticals (MDGL) Competitors

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.

Which has stronger valuation & earnings, BIIB or MDGL?

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.82B	1.80	$1.63B	$10.13	11.88
Madrigal Pharmaceuticals	$317.38M	19.79	-$373.63M	-$18.05	-15.67

Does the MarketBeat Community prefer BIIB or MDGL?

Biogen received 1358 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 68.03% of users gave Madrigal Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1824 71.28%	Underperform Votes 735 28.72%
Madrigal Pharmaceuticals	Outperform Votes 466 68.03%	Underperform Votes 219 31.97%

Do institutionals & insiders hold more shares of BIIB or MDGL?

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 22.8% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more volatility and risk, BIIB or MDGL?

Biogen has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.91, suggesting that its stock price is 191% less volatile than the S&P 500.

Does the media refer more to BIIB or MDGL?

In the previous week, Biogen had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 18 mentions for Biogen and 16 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.37 beat Biogen's score of 1.19 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	12 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BIIB or MDGL more profitable?

Biogen has a net margin of 16.87% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%

Do analysts recommend BIIB or MDGL?

Biogen currently has a consensus target price of $191.30, suggesting a potential upside of 58.92%. Madrigal Pharmaceuticals has a consensus target price of $416.33, suggesting a potential upside of 47.19%. Given Biogen's higher probable upside, equities research analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
Madrigal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Biogen beats Madrigal Pharmaceuticals on 13 of the 18 factors compared between the two stocks.